# Sunshine Lake Pharma (HEC)

Source: https://onco.cc/companies/sunshine-lake-pharma/  
OnCo record `sunshine-lake-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sunshine Lake Pharma, the pharmaceutical arm of China's HEC group based in Dongguan, is running phase 3 trials of clifutinib, a FLT3 inhibitor for acute myeloid leukaemia, and lerotinib in oesophageal cancer.

## Summary

Sunshine Lake Pharma, part of the HEC (Dongyangguang) group in Dongguan, Guangdong, is a Chinese pharmaceutical company with antiviral, metabolic and oncology pipelines. In cancer it is developing clifutinib, a small-molecule FLT3 inhibitor in a phase 3 trial for FLT3-mutated acute myeloid leukaemia, and lerotinib, a small-molecule kinase inhibitor in a phase 3 trial for oesophageal cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the group website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Sunshine Lake Pharma Co., Ltd.; HEC Pharm
- Tags: ctgov-sponsor
- HQ: Dongguan
- Type: pharma
- Website: https://www.hec.cn/

## Sources

- HEC group website: https://www.hec.cn/
- ClinicalTrials.gov: trials led by Sunshine Lake Pharma: https://clinicaltrials.gov/search?lead=Sunshine%20Lake%20Pharma

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Clifutinib](https://onco.cc/drugs/clifutinib/), [Lerotinib](https://onco.cc/drugs/lerotinib/)
- trials: [A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML](https://onco.cc/trials/nct05133882/), [HEC169096 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05451602/), [HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML](https://onco.cc/trials/nct05586074/), [Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer](https://onco.cc/trials/nct04415853/)

---
JSON: https://onco.cc/api/v1/entities/sunshine-lake-pharma.json